JNJ-40255293 is an adenosine A2A/A1 antagonist with efficacy in preclinical models of parkinson's disease. References: Atack JR, Shook BC, Rassnick S, Jackson PF, Rhodes K, Drinkenburg WH, Ahnaou A, Te Riele P, Langlois X, Hrupka B, De Haes P, Hendrickx H, Aerts N, Hens K, Wellens A, Vermeire J, Megens AA. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease. ACS Chem Neurosci. 2014 Oct 15;5(10):1005-19. doi: 10.1021/cn5001606. Epub 2014 Sep 24. PubMed PMID: 25203719.

纯度：≥98%

CAS：1147271-25-7